Novavax Inc. (NVAX.O) said on Friday its experimental COVID-19 vaccine demonstrated an immune response and protection against the highly contagious coronavirus variant originally identified in a clinical trial in South Africa.
The vaccine NVX-CoV2373 is being tested in several studies, but has yet to be approved in one country.
Novavax also said that studies in mice and baboons found that another vaccine, specifically targeting the South African variant now known as Beta, produced an immune response and protection, and is expected to be more clinical in the fall Perform testing of the beta-focused vaccine.
The company said tests of blood serum from thirty mid-stage participants in a study who received both doses of NVX-CoV2373 showed robust antibody responses against the original version of the coronavirus, as well as the alpha variant first found in the UK and US beta -Variant.
However, the reaction against the beta variant was somewhat lower, according to Novavax.
The European Medicines Agency started an ongoing review of the Novavax syringe in February. The data from the pivotal study in the United States and Mexico are expected to be published in the current quarter.
The company announced that the new data is available on the bioRxiv online preprint server and has been submitted for assessment.
Our standards: The Thomson Reuters Trust Principles.